180 related articles for article (PubMed ID: 11270321)
1. Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients.
Ericsson H; Schwieler J; Lindmark BO; Löfdahl P; Thulin T; Regårdh CG
Chirality; 2001; 13(3):130-4. PubMed ID: 11270321
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.
Ericsson H; Tholander B; Björkman JA; Nordlander M; Regårdh CG
Drug Metab Dispos; 1999 May; 27(5):558-64. PubMed ID: 10220482
[TBL] [Abstract][Full Text] [Related]
3. Clevidipine for the treatment of severe hypertension in adults.
Nguyen HM; Ma K; Pham DQ
Clin Ther; 2010 Jan; 32(1):11-23. PubMed ID: 20171407
[TBL] [Abstract][Full Text] [Related]
4. Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
Ericsson H; Fakt C; Jolin-Mellgård A; Nordlander M; Sohtell L; Sunzel M; Regårdh CG
Br J Clin Pharmacol; 1999 May; 47(5):531-8. PubMed ID: 10336577
[TBL] [Abstract][Full Text] [Related]
5. Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension.
Kenyon KW
Ann Pharmacother; 2009 Jul; 43(7):1258-65. PubMed ID: 19584385
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.
Smith WB; Marbury TC; Komjathy SF; Sumeray MS; Williams GC; Hu MY; Mould DR
Eur J Clin Pharmacol; 2012 Oct; 68(10):1385-94. PubMed ID: 22457015
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
Ericsson H; Bredberg U; Eriksson U; Jolin-Mellgård A; Nordlander M; Regårdh CG
Anesthesiology; 2000 Apr; 92(4):993-1001. PubMed ID: 10754618
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass.
Vuylsteke A; Milner Q; Ericsson H; Mur D; Dunning J; Jolin-Mellgård A; Nordlander M; Latimer R
Br J Anaesth; 2000 Nov; 85(5):683-9. PubMed ID: 11094580
[TBL] [Abstract][Full Text] [Related]
9. Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
Cerqueira PM; Cesarino EJ; Mateus FH; Mere Y; Santos SR; Lanchote VL
Chirality; 1999; 11(7):591-7. PubMed ID: 10423287
[TBL] [Abstract][Full Text] [Related]
10. In vitro hydrolysis rate and protein binding of clevidipine, a new ultrashort-acting calcium antagonist metabolised by esterases, in different animal species and man.
Ericsson H; Tholander B; Regårdh CG
Eur J Pharm Sci; 1999 Apr; 8(1):29-37. PubMed ID: 10072476
[TBL] [Abstract][Full Text] [Related]
11. Steady-state pharmacokinetics of propranolol enantiomers in healthy male volunteers.
Paradiso-Hardy FL; Walker SE; Bowles SK
Int J Clin Pharmacol Ther; 1998 Jul; 36(7):370-5. PubMed ID: 9707351
[TBL] [Abstract][Full Text] [Related]
12. Clevidipine in adult cardiac surgical patients: a dose-finding study.
Bailey JM; Lu W; Levy JH; Ramsay JG; Shore-Lesserson L; Prielipp RC; Brister NW; Roach GW; Jolin-Mellgard A; Nordlander M
Anesthesiology; 2002 May; 96(5):1086-94. PubMed ID: 11981147
[TBL] [Abstract][Full Text] [Related]
13. Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension.
Pollack CV; Varon J; Garrison NA; Ebrahimi R; Dunbar L; Peacock WF
Ann Emerg Med; 2009 Mar; 53(3):329-38. PubMed ID: 18534716
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.
Ericsson H; Fakt C; Höglund L; Jolin-Mellgård A; Nordlander M; Sunzel M; Regårdh CG
Eur J Clin Pharmacol; 1999 Mar; 55(1):61-7. PubMed ID: 10206087
[TBL] [Abstract][Full Text] [Related]
15. Clevidipine (Cleviprex) for IV treatment of severe hypertension.
Med Lett Drugs Ther; 2008 Sep; 50(1295):73-4. PubMed ID: 18800023
[No Abstract] [Full Text] [Related]
16. Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials.
Aronson S
Expert Rev Cardiovasc Ther; 2009 May; 7(5):465-72. PubMed ID: 19419254
[TBL] [Abstract][Full Text] [Related]
17. The use of physiologically based models to simulate enantioselective differences in pharmacokinetics.
Piotrovskij VK; Shvatchko EV; Trnovec T
Methods Find Exp Clin Pharmacol; 1994 May; 16(4):263-9. PubMed ID: 8051986
[TBL] [Abstract][Full Text] [Related]
18. Clevidipine for controlled hypotension during spinal surgery in adolescents.
Tobias JD; Hoernschemeyer DG
J Neurosurg Anesthesiol; 2011 Oct; 23(4):347-51. PubMed ID: 21623231
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of thiamylal enantiomers in humans.
Sueyasu M; Ikeda T; Taniyama T; Futugami K; Kataoka Y; Oishi R
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):128-32. PubMed ID: 9089003
[TBL] [Abstract][Full Text] [Related]
20. Circulatory effects and pharmacology of clevidipine, a novel ultra short acting and vascular selective calcium antagonist, in hypertensive humans.
Schwieler JH; Ericsson H; Löfdahl P; Thulin T; Kahan T
J Cardiovasc Pharmacol; 1999 Aug; 34(2):268-74. PubMed ID: 10445679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
